Perspectives - Page 14

Supporting a Medical Device Client with Strategy, Analytics, and Communication Capabilities Across Therapy Areas

Read about a client who tapped into a range of Lumanity offerings, enabling them to not only have a comprehensive MS campaign, but to also start strategizing at the portfolio level across a breadth of therapeutic areas.

Case Study Mar 1, 2023

Medical Affairs Unscripted | Achieving Global Field Medical Excellence with Robin Winter-Sperry, MD

Podcast Mar 1, 2023

Finding Optimism and Advocacy Through Adversity

On-Demand Webinar Feb 28, 2023

Journey to Insight and Inspiration

View Feb 27, 2023

Weathering the Storm: Portfolio Diversification Strategies to Ensure Life-saving Advanced Therapeutics Reach Rare Disease Patients Amidst the Market Downturn

View Feb 24, 2023

Unsure About the EU HTA Regulation?

Lumanity’s EU Head of Health Economics and Statistics, Suzette Matthijsse, explores the results of our EU HTA Regulation market survey.

View Feb 23, 2023

The New Burden of Proof: Platform, Concept and Relevance

On-Demand Webinar Feb 17, 2023

Inflation Reduction Act and Maximum Fair Price: Possible Industry and Practice Impacts

View Feb 14, 2023

Inflation Reduction Act and Potential Impacts to BioPharma

On-Demand Webinar Feb 10, 2023

Fundraising in 2023: The Post JP Morgan/Biotech Showcase Outlook For Early-Stage Companies

View Feb 9, 2023

Opportunities for Enhanced Communication between Manufacturers and US Payers (Part 3)

In part three of our series, ‘Opportunities for Enhanced Communication between Manufacturers and US Payers’, our experts explore the tools manufacturers can use to communicate HCEI to payers, insights from the Food and Drug Administration (FDA) guidance on payer communications, and practical considerations to optimize these interactions.

View Feb 6, 2023

Medical Affairs Unscripted | Our Medical Affairs Journey Continues, with Dr Peg Crowley-Nowick, PhD, MBA

Podcast Jan 30, 2023

Opportunities for Enhanced Communication between Manufacturers and US Payers (Part 2)

View Jan 20, 2023

The Importance of Engaging Patients and Patient Advocates Throughout the Medicine Development Cycle

View Jan 18, 2023

Do You Really Know How Your Market Works?

Whitepaper Jan 18, 2023

Opportunities for Enhanced Communication between Manufacturers and US Payers (Part 1)

In the first in a three-part series, our Value Strategy and Services team in the United States provide an introduction to Pre-Approval Information Exchange and communicating Health Care Economic Information to payer audiences, including exploring current US Food and Drug Administration (FDA) guidance on payer communications.

View Jan 9, 2023